To the Editor,

We read with great interest the article "The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation" by Bösmüller and colleagues describing pulmonary changes in 4 patients deceased from COVID-19 \[[@CR1]\]. Besides the different stages of diffuse alveolar damage (DAD), the authors also describe vascular changes, in particular micro- and macrothrombosis of pulmonary arteries and infarction or infarct-like changes of the surrounding pulmonary parenchyma in association with endothelitis. It is reassuring to see that this paper convincingly confirms the key findings of our study (published May 14) which has demonstrated pulmonary arterial thrombosis as an important and so far, underrecognized complication of SARS-CoV-2--associated pulmonary disease \[[@CR2]\]. In our study on 11 COVID-19 deceased, we also described the different stages of DAD from alveolar edema and hyaline membranes to proliferation of alveolar macrophages and organization by fibrosis. Similar changes have been previously found in SARS-1 but may also be present in acute respiratory distress syndrome (ARDS) by other causes such as the different types of shock. COVID-19 pulmonary arterial thrombosis with subsequent occlusion of small- and mid-sized arteries leads to a massive breakdown of pulmonary circulation and oxygenation. Thrombotic occlusion of pulmonary arteries has been described in the older literature as a complication of ARDS including an intent of treatment by streptokinase infusion \[[@CR3]\] and more recently in pediatric ARDS. The issue of thromboembolism versus thrombosis in COVID-19 pulmonary disease has led to an intense discussion \[[@CR4], [@CR5]\]. In particular, the location in the subsegmental arteries, the pattern of distribution of the thrombotic material in multiple vessels (as demonstrated in our and the present paper by gross figures), the associated endothelitis, as well as the subtotal or total filling of the vessels favors in situ thrombosis \[[@CR2]\]. In addition, these occluded vessels are almost exclusively found in areas of hypostasis, whereas thromboemboli would be randomly distributed and also found in well-ventilated areas of the lungs. Fixation of the total lungs in formalin and serial sectioning as performed by us and others facilitate the detection of these pulmonary arteries occluded by thrombotic material in contrast to a sampling of fresh lung tissue during autopsy \[[@CR2]\]. These findings seem to have a tremendous clinical impact, although at the moment, an effective therapeutic strategy is still lacking. Prophylactic anticoagulation is certainly justified but may be ineffective to prevent thrombosis as seen in our study and other studies \[[@CR2]\]. On the other hand, therapeutic anticoagulation could be effective but lacks evidence by controlled clinical trials and also has risks such as bleeding into the lung parenchyma and other sites \[[@CR4]\].

In conclusion, severe and fatal course of COVID-19 seems to be caused not only by the inflammatory reaction of the lung parenchyma but also frequently by thrombotic occlusion of small- to mid-sized pulmonary arteries and subsequent infarction of lung parenchyma as it can be found in ARDS of different pathogenesis.
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